NASDAQ: ENSG

Ensign (ENSG) Stock Analysis & Forecast

Nov 13 close

$188.41+1.86 (+1.0%)

Gekko Brief

Nov 9 close

Ensign closed at $182.10 on 9 November 2026, +0.6% on the day. The price sits between the 50-day ($175.39) and 200-day ($181.76) moving averages, inside a 52-week range of $141.58 to $218.00. The GekkoIndex reads 54.2, in the Neutral zone, up 0.2 points over five sessions. Gekko Fair Value is $165.21, so the price is 10.2% above it.

The next earnings report is due on 3 February 2027, 80 days away. Over the last 8 reports the company beat the earnings estimate 8 times, with an average move of 5.4% across the report. Seasonally, the next 20 trading days from this point averaged -0.2% over the last 5 years, rising in 2 of them.

4 firms rate the stock: 3 buy, 1 hold and 0 sell, with a consensus target of $225.80. A typical daily move is about 3.5%, and a typical 20-day move about 4.7%. On the swing-trade checklist, 1 item reads supportive and 2 read as a headwind (fair value, seasonality).

A plain summary of the figures as of the Nov 9, 2026 close.

Ensign price vs fair value

$188.41$162.99Nov ’25May ’26Nov ’26
Close $188.41200-day averageGekko Fair Value $162.99

Ensign quick facts

Market cap
$10.99B
P/E ratio
27.7
Forward P/E
21.3
EPS, TTM
$6.73
Revenue, TTM
$5.67B
Profit margin
7%
Dividend yield
0.14%
Beta
0.65
Volume
254,732 avg 400,977
1-year return
+4.8%
Typical daily move
±3.2%
Typical 20-day move
±4.7%
50-day average
$176.51
200-day average
$182.03
Next earnings
Feb 3
Shares outstanding
58.34M
52-week range
$141.58$218.00

Ensign swing-trade checklist

Ensign scores 1 supportive, 2 mixed and 2 headwinds across the 5 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

1 supportive2 mixed2 headwinds

  • Trendmixed

    Averages disagree

    Close $188.41 sits between the 50-day ($176.51) and 200-day ($182.03) averages, or the averages disagree.

    See the chart
  • GekkoIndexmixed

    52.1, Neutral

    Reading 52.1 is in the Neutral zone.

    See the GekkoIndex
  • Fair valueheadwind

    15.6% above

    Price is 15.6% above Gekko Fair Value (more than 5% above).

    See fair value
  • Smart moneyno data

    No data

    No insider, Congress or unusual options activity in the window.

    See smart money
  • Earnings risksupportive

    Reports in 80 days

    Next report Feb 3, 2027, 80 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalityheadwind

    −0.4% on average

    From this point in the calendar, the next 20 trading days averaged −0.4% over 5 years, rising in 2 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

Ensign stock chart and price history

Ensign closed at $188.41 on Nov 13, 2026, +4.8% over the past year, inside a 52-week range of $141.58 to $218.00.

Close50-day average200-day averageVolume
Ensign share price, past year, with 50-day and 200-day moving averages and volume$160$180$200DecJan 2026FebMarAprMayJunJulAugSepOctNov188.41

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
+5.8%
3 months
+3.8%
6 months
+6.0%
1 year
+4.8%
The full ENSG chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open ENSG in Gekko

Follow Ensign through every session

Put ENSG on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track ENSG in GekkoFree for 7 days. No credit card required.

About Ensign

Ensign works in post-acute healthcare, offering nursing care for people recovering from prolonged illness, managing ongoing health conditions, or needing elder care. It is known for combining medical treatment with everyday support such as housing, meal planning, and recreational activities for residents. Its services extend to rehabilitative therapies including physical, occupational, and speech therapy, as well as senior living facilities and mobile diagnostic offerings like X-rays, ultrasounds, and lab work.

The company runs through two divisions, Skilled Services and Real Estate. The Skilled Services arm covers the clinical and residential care work described above, along with sub-acute care and patient transport to and from homes or long-term facilities. The Real Estate arm involves leasing property. Together these divisions supported a network of 252 healthcare facilities located across thirteen U.S. states, including California, Texas, Arizona, and Washington, as of April 2022.

Ensign was founded in 1999 and is based in San Juan Capistrano, California. Its shares are listed on the NASDAQ under the ticker ENSG.

Listed
NASDAQ
Sector
Health services
Industry
Medical/Nursing services
Website
ensigngroup.net

Ensign GekkoIndex: the smart money zone

Ensign’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 52.1, in the Neutral zone, down 2.8 points over five sessions.

010052.1Neutral

Down 2.8 points over five sessions.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying27+0.4%+1.4%+2.5%+6.1%
Accumulation230+0.4%+0.7%+1.4%+3.5%
Neutral (current zone)401+0.4%+0.7%+1.6%+3.7%
Distribution43+0.4%+1.6%+1.1%+0.3%
Selling1Too few readings yet

Average ENSG share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.

Neutral zone: No clear directional signal. About the five zones →

See every daily GekkoIndex reading plotted over the ENSG price, zone by zone.Track ENSG in Gekko

Is Ensign stock overvalued? Gekko Fair Value

Ensign trades 15.6% above Gekko Fair Value of $162.99, so the shares are overvalued on Gekko’s estimate.

Gekko’s own estimate of what Ensign shares are worth, recalculated every trading day.

$162.99

Gekko Fair Value, Nov 14, 2026

15.6% Overvalued

At the end of Aug 2026 the price was 5.8% above the estimate.

Gekko Fair ValueShare price, month end
$163$188Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open ENSG in Gekko

Ensign insider and Congress trading

No open-market insider purchases were filed for Ensign, and no Congress trades were disclosed, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for ENSG in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every ENSG insider filing, plotted on the chart in Gekko.Open ENSG in Gekko

Congress trades last 90 days

No trades in ENSG were disclosed by members of Congress in the last 90 days.

From congressional disclosures, which report amounts as ranges.

Congress disclosures for ENSG, plotted on the chart in Gekko.Open ENSG in Gekko

Buybacks

Ensign has been buying back its own shares.

Latest authorization
$100.0M, Jun 15, 2026
Bought back, quarter ended Sep 30, 2026
$7.43M
As a share of market cap
0.07%
Trailing four quarters
$48.77M

From company filings.

Hedge funds and billionaires quarter ended Dec 31

1of the funds Gekko tracks holds ENSG.

1added0opened0trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko

Ensign earnings: next date and track record

Ensign reports on Feb 3, 2027 (80 days away), and beat the EPS estimate in 8 of its last 8 reports.

8 of 8reports beat the EPS estimate
±5.4%average move across the report
6 of 8reports followed by a gain

Share-price move across each report

−6.5%Feb ’25+1.5%Apr ’25+7.8%Jul ’25+2.2%Nov ’25+13.6%Feb ’26−1.4%Apr ’26+5.9%Jul ’26+4.1%Oct ’26

Last earnings call, Oct 27, 2026 AI summary

What they said
Ensign Group reported Q3 2026 results described as 'outstanding,' with management emphasizing their integrated care model (1 CLINICAL) and culture-driven operating approach across nearly 60,000 employees. The company operates skilled nursing facilities with a differentiated therapy-integrated clinical strategy. Financial specifics were not yet disclosed in this excerpt, but tone suggests strong operational and clinical performance continuity.
Guidance
No specific financial guidance, revenue targets, or EPS figures were provided in this transcript excerpt. Management's forward-looking commentary focused on clinical strategy and culture as drivers of sustainable performance.
ReportedEPSSurpriseRevenueSurpriseMove
Oct 27, 2026$2.03
est $1.97
+3.0%$1.48B
est $1.51B
−1.5%+4.1%
Jul 27, 2026$1.92
est $1.80
+6.7%$1.44B
est $1.44B
−0.1%+5.9%
Apr 30, 2026$1.85
est $1.82
+1.6%$1.39B
est $1.40B
−0.5%−1.4%
Feb 4, 2026$1.82
est $1.75
+4.0%$1.36B
est $1.37B
−0.5%+13.6%
Nov 3, 2025$1.64
est $1.59
+3.1%$1.30B
est $1.37B
−5.2%+2.2%
Jul 24, 2025$1.59
est $1.55
+2.6%$1.23B
est $1.22B
+0.7%+7.8%
Apr 29, 2025$1.52
est $1.49
+2.0%$1.17B
est $1.17B
+0.1%+1.5%
Feb 5, 2025$1.49
est $1.48
+0.7%$1.13B
est $1.13B
+0.3%−6.5%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

Ensign stock forecast and analyst price targets

Analysts’ average 12-month price target for Ensign is $225.80, +19.8% from the last close, from 4 firms rating the stock in the last 90 days.

$225.80consensus 12-month target, +19.8% from the last close
Low $210High $240
Buy3
Hold1
Sell0

Each firm’s latest rating in the last 90 days: 4 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Oct 29UBSBuy, reiterated$240+27.4%
Oct 29OppenheimerBuy, maintained$215+14.1%
Oct 29StephensBuy, reiterated$225+19.4%
Oct 29Truist FinancialHold, maintained$210+11.5%
Oct 27UBSBuy, maintained$230+22.1%
+1.6%average 20-day move after past Neutral readings
−0.4%average move over the next 20 trading days in the last 5 years
±3.2%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

Ensign seasonality: the next 20 trading days

Over the next 20 trading days from Nov 14, Ensign averaged −0.4% across the last 5 years, rising in 2 of them.

Next 20 trading days, by year

−2.9%2021+1.4%2022+4.8%2023−2.2%2024−0.4%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days+1.0%4 of 5
Next 10 trading days−0.6%3 of 5
Next 15 trading days−1.4%1 of 5
Next 20 trading days−0.4%2 of 5
Next 30 trading days+0.5%3 of 5

For scale, ENSG’s typical 20-trading-day move in either direction is about 4.7%.

Ensign market cap and key statistics

Ensign’s market cap is $10.99B, with a P/E ratio of 27.7 and revenue of $5.67B over the last twelve months.

Valuation

Market cap
$10.99B
P/E ratio
27.7
Forward P/E
21.3
EPS, TTM
$6.73
Gekko Fair Value
$162.99

Trading

Volume
254,732
Avg volume, 20 days
400,977
52-week high
$218.00
52-week low
$141.58
Shares outstanding
58.34M

Financials

Revenue, TTM
$5.67B
Profit margin
7%
Return on equity
17.1%
Quarterly earnings growth, YoY
+23.9%

Risk and income

Beta
0.65
Typical daily move
±3.2%
Typical 20-day move
±4.7%
Dividend yield
0.14%

Ensign peers

Ensign’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
LHLabcorp−1.0%Neutral8.5% above
GHGuardant Health−2.8%Accumulation16.4% below
SOLVSolventum0.0%Neutral17.0% below
BTSGBrightSpring Health Services0.0%Neutral11.0% above
EHCEncompass Health−0.4%Neutral14.7% above
DVADaVita−0.3%Accumulation25.6% below

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Medical/Nursing services

Ensign stock FAQ

What is Ensign’s market cap?

Ensign’s market cap is $10.99B at the Nov 13, 2026 close of $188.41, with 58.34M shares outstanding. The shares trade on a P/E ratio of 27.7.

What is the Ensign stock forecast?

The consensus analyst 12-month price target for Ensign is $225.80, +19.8% from the last close. Of the 4 firms that rated the stock in the last 90 days, 3 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.

Is Ensign stock overvalued or undervalued?

On Gekko’s estimate Ensign is overvalued: the Nov 13, 2026 close of $188.41 is 15.6% above Gekko Fair Value of $162.99. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does Ensign report earnings next?

Ensign is expected to report on Feb 3, 2027 (80 days away). Analysts expect earnings of $2.16 per share on revenue of $1.60B. Ensign beat the earnings estimate in 8 of its last 8 reports, moving 5.4% on average across the report.

What is Ensign’s 52-week high and low?

Ensign’s 52-week high is $218.00 and its 52-week low is $141.58; it closed at $188.41 on Nov 13, 2026, +4.8% over the past year.

Is Ensign stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 1 of the 5 items with data read as supportive (earnings risk), 2 as mixed (trend and gekkoindex) and 2 as headwinds (fair value and seasonality). The checklist is a description of current data, not a recommendation.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See Ensign the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.